Inebilizumab-cdon, commercially known as Uplinza, is an innovative immunomodulatory agent developed by Viela Bio, now a part of Horizon Therapeutics USA.

Tisagenlecleucel, marketed under the brand name Kymriah, is a pioneering immunotherapy medication developed by Novartis.

Lisocabtagene maraleucel, marketed under the brand name Breyanzi, is a revolutionary immunotherapy medication developed by Bristol-Myers Squibb.

Avibactam / Ceftazidime, commercially known as Avycaz, is an antibiotic combination developed by AstraZeneca.

Semaglutide, a cutting-edge medication, has been making significant strides in the treatment of type 2 diabetes, weight loss, and reducing cardiovascular risk.